- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03083678
Afatinib in Locally Advanced and Metastatic Chordoma
April 19, 2022 updated by: HansGelderblom, Leiden University Medical Center
A Phase 2, Single Arm, European Multi-center Trial Evaluating the Efficacy of Afatinib as First-line or Later-line Treatment in Advanced Chordoma.
In this phase 2, single arm trial patients with locally advanced or metastatic, pathologically proven, EGFR expressing chordoma will be treated with afatinib.
Two cohorts of patients will be included: 20 first line patients and 20 second or further line patients.
The treatment will be given in 4 week cycles until disease progression.
Median PFS according to RECIST 1.1 will be evaluated.
The objective is to increase the median PFS ≥ 12 months in first-line treatment cohort and ≥ 9 months in later-line treatment cohort.
Additional exploratory research will be performed, consisting of a pharmacokinetic study and translational studies on EGFR pathway activation and signalling on blood and tumor samples.
Study Overview
Study Type
Interventional
Enrollment (Actual)
43
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Milan, Italy
- Istituto Nazionale dei Tumori: Fondazione IRCCS
-
-
-
-
-
Leiden, Netherlands
- Leiden University Medical Center
-
-
-
-
-
London, United Kingdom
- University College London Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Locally advanced or metastatic, pathologically proven, EGFR expressing chordoma, not amenable for local therapies
- Patients of 18 years and up
- Documented radiographic progression of disease according to RECIST 1.1 criteria in last 6 months
- ECOG Performance status ≤ 2
- Adequate bone marrow function (Hb ≥ 6.0 mmol/L, absolute neutrophil count ≥ 1.5 x 109/L, platelets ≥ 75 x 109/L)
- An adequate renal function with GFR ≥ 45 ml/min calculated by Cockroft-Gault formula
- Total Bilirubin ≤ 1.5 times upper limit of normal (ULN) (Patients with Gilbert's syndrome total bilirubin must be ≤4 times institutional upper limit of normal).
- Aspartate amino transferase (AST) or alanine amino transferase (ALT) ≤ 3 times ULN (if related to liver metastases ≤ 5 times ULN)
- Ability to swallow medication
- Recovered from any previous therapy related toxicity to ≤ grade 1 at study entry (except for stable sensory neuropathy ≤ grade 2 and alopecia)
- Availability of archival tumor material for central review (if not please obtain a new tumor biopsy)
- Written signed informed consent
- Ability to adhere to the study visits and all protocol requirements
Exclusion Criteria:
- Life expectancy of less than 3 months
- No measurable lesions according to RECIST 1.1
- Known hypersensitivity to afatinib
- Major surgery less than 4 weeks prior to start of treatment
- Previous treatment with any other investigational agents within 14 days of first day of study drug dosing
- History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of ≥ 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to inclusion.
- Known pre-existing interstitial lung disease
- Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn's disease, ulcerative colitis, chronic diarrhea, malabsorption)
- Known active hepatitis B infection (defined as presence of HepB sAg and/ or Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier.
- Systemic anti-cancer therapy within 28 days prior to the first dose of study drug , or radiotherapy to an index (or target)lesion within 21 days prior to the first dose of study drug
- Requiring treatment with any of the prohibited concomitant medications listed in Section 6.3.9 that cannot be stopped for the duration of trial participation
- Pregnant or lactating women
- Other invasive malignancies diagnosed within the last 5 years, except non-melanoma skin cancer and localized cured prostate and cervical cancer
- Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Afatinib
Afatinib active treatment.
|
Afatinib will be given daily in a dose of 40 mg orally in a 4 week cycle until disease progression or patient withdrawal.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median PFS according to RECIST 1.1 criteria on afatinib treatment (first-line cohort)
Time Frame: From date of start treatment until date of first documented of progression or withdrawal (through study completion, an average of 1 year).
|
The objective is to increase the median PFS ≥ 12 months in first-line treatment cohort.
|
From date of start treatment until date of first documented of progression or withdrawal (through study completion, an average of 1 year).
|
Median PFS according to RECIST 1.1 criteria on afatinib treatment (second or later line cohort)
Time Frame: From date of start treatment until date of first documented of progression or withdrawal (through study completion, an average of 1 year).
|
The objective is to increase the median PFS ≥ 9 months in later-line treatment cohort.
|
From date of start treatment until date of first documented of progression or withdrawal (through study completion, an average of 1 year).
|
Quality of life assessment by EORTC QLC-30 questionnaire.
Time Frame: From date of start treatment until date of first documented of progression of withdrawal (through study completion, an average of 1 year).
|
Change from baseline in EORTC QLC-30 questionnaire score.
|
From date of start treatment until date of first documented of progression of withdrawal (through study completion, an average of 1 year).
|
Quality of life assessment by Brief pain inventory short form
Time Frame: From date of start treatment until date of first documented of progression of withdrawal (through study completion, an average of 1 year).
|
Change from baseline on Brief pain inventory short form score.
|
From date of start treatment until date of first documented of progression of withdrawal (through study completion, an average of 1 year).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Growth modulation index.
Time Frame: From date of start treatment until date of first documented of progression (through study completion, an average of 1 year).
|
Time to progression during afatinib treatment (TTP2) divided by time to progression before start of this treatment TTP1 (= growth modulation index)
|
From date of start treatment until date of first documented of progression (through study completion, an average of 1 year).
|
Toxicity determined by CTCAE v 4.03 criteria
Time Frame: From date of start treatment until date of first documented of progression or withdrawal (through study completion, an average of 1 year).
|
Toxicity determined by CTCAE v 4.03 criteria
|
From date of start treatment until date of first documented of progression or withdrawal (through study completion, an average of 1 year).
|
Overall survival.
Time Frame: Survival follow-up after end of treatment every 3 months for up to 2 years followed by contact at 3 years.
|
Overall survival from start of afatinib treatment
|
Survival follow-up after end of treatment every 3 months for up to 2 years followed by contact at 3 years.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Translational research - EGFR pathway analysis in tumor tissue
Time Frame: From date of inclusion until date of first documented of progression or withdrawal (through study completion, an average of 1 year)
|
EGFR status by FISH / immunohistochemistry
|
From date of inclusion until date of first documented of progression or withdrawal (through study completion, an average of 1 year)
|
Translational research - Genome sequence analysis of available tumor samples
Time Frame: From date of inclusion until date of first documented of progression or withdrawal (through study completion, an average of 1 year)
|
Genetic mutations by DNA whole genome sequencing of fresh samples
|
From date of inclusion until date of first documented of progression or withdrawal (through study completion, an average of 1 year)
|
Translational research - circulating tumor DNA
Time Frame: Analysis on blood samples to be taken at baseline, cycle 4 day 1, cycle 7 day 1 and at end of treatment (within 30 days after last dose of study drug).
|
Circulating chordoma tumor DNA identification by WGS and PCR
|
Analysis on blood samples to be taken at baseline, cycle 4 day 1, cycle 7 day 1 and at end of treatment (within 30 days after last dose of study drug).
|
Translational research - circulating exosomes
Time Frame: Analysis on blood samples to be taken at different time points on cycle 1 day 1, cycle 1 day 15, cycle 3 day 1 and cycle 5 day 1.
|
Circulating exosomes identification by PCR
|
Analysis on blood samples to be taken at different time points on cycle 1 day 1, cycle 1 day 15, cycle 3 day 1 and cycle 5 day 1.
|
Pharmacokinetic research
Time Frame: Analysis on blood samples to be taken at different time points on cycle 1 day 1, cycle 1 day 15, cycle 3 day 1 and cycle 5 day 1.
|
Area under the curve
|
Analysis on blood samples to be taken at different time points on cycle 1 day 1, cycle 1 day 15, cycle 3 day 1 and cycle 5 day 1.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: AJ Gelderblom, Prof, Leiden University Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 21, 2018
Primary Completion (Anticipated)
July 1, 2023
Study Completion (Anticipated)
October 1, 2023
Study Registration Dates
First Submitted
February 10, 2017
First Submitted That Met QC Criteria
March 13, 2017
First Posted (Actual)
March 20, 2017
Study Record Updates
Last Update Posted (Actual)
April 20, 2022
Last Update Submitted That Met QC Criteria
April 19, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1200.277
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chordoma
-
Jonsson Comprehensive Cancer CenterBristol-Myers SquibbCompletedChordoma | Metastatic Chordoma | Unresectable Chordoma | Locally Advanced ChordomaUnited States
-
M.D. Anderson Cancer CenterRecruitingChordoma | Metastatic Chordoma | Unresectable ChordomaUnited States
-
Institut CurieActive, not recruitingSkull Base Chordoma | Vertebral ChordomaFrance
-
Heidelberg UniversityActive, not recruiting
-
Huashan HospitalBoehringer IngelheimNot yet recruiting
-
Xuanwu Hospital, BeijingRecruiting
-
Massachusetts General HospitalM.D. Anderson Cancer Center; National Cancer Institute (NCI)Active, not recruitingChordoma of Sacrum | Chordoma of Spine | Chordoma of Base of Skull | Chondrosarcoma of the Spine | Chondrosarcoma of the SacrumUnited States
-
CNAO National Center of Oncological HadrontherapyDept. of Electronics, Informatics, Bioengineering, Politecnico di Milano,...Recruiting
-
National Cancer Institute (NCI)RecruitingGenes | Sporadic ChordomaUnited States
-
Hospices Civils de LyonRecruitingMalignant Tumors as Chordoma, Adenoid Cystic Carcinoma and SarcomaFrance
Clinical Trials on Afatinib
-
Boehringer IngelheimCompleted
-
University of ChicagoNational Cancer Institute (NCI)RecruitingRecurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Ureter Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent Urethral Cancer | Stage III Urethral Cancer | Stage IV Urethral CancerUnited States
-
Centre Leon BerardBoehringer IngelheimCompletedHead and Neck Squamous Cell CarcinomaFrance
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimNo longer available
-
University College, LondonBoehringer IngelheimCompletedCarcinoma, Non-Small-Cell LungUnited Kingdom
-
Boehringer IngelheimCompletedCarcinoma, Non-Small-Cell LungKorea, Republic of
-
Boehringer IngelheimTerminatedNeoplasmsUnited States, Taiwan
-
Boehringer IngelheimApproved for marketing
-
Boehringer IngelheimCompletedCarcinoma, Non-Small-Cell LungGreece